Logo

Invitrogen, ABI to Mail Merger Prospectus to Shareholders This Week

Sep 11, 2008
NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems said today that the registration statement for their proposed $6.7 billion merger has become effective, and the firms will mail a joint proxy statement/prospectus to their respective shareholders this week.
 
Each firm will hold a special meeting of shareholders on Oct. 16 to vote on the proposed deal. ABI and Invitorgen shareholders of record as of the close of business on Sept. 5 are entitled to vote at the meetings.

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.